NexImmune, Inc.
NEXI
$0.00
$0.000.00%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.62M | 11.44M | 13.13M | 14.50M | 14.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.06M | 22.12M | 29.18M | 44.85M | 49.71M |
| Operating Income | -17.06M | -22.12M | -29.18M | -44.85M | -49.71M |
| Income Before Tax | -20.62M | -25.86M | -32.34M | -43.88M | -48.75M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.62 | -25.86 | -32.34 | -43.88 | -48.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.62M | -25.86M | -32.34M | -43.88M | -48.75M |
| EBIT | -17.06M | -22.12M | -29.18M | -44.85M | -49.71M |
| EBITDA | -16.38M | -21.24M | -28.16M | -43.79M | -48.66M |
| EPS Basic | -18.59 | -24.16 | -30.86 | -42.01 | -47.69 |
| Normalized Basic EPS | -9.03 | -12.86 | -17.00 | -26.25 | -29.81 |
| EPS Diluted | -18.59 | -24.16 | -30.86 | -42.01 | -47.69 |
| Normalized Diluted EPS | -9.03 | -12.86 | -17.00 | -26.25 | -29.81 |
| Average Basic Shares Outstanding | 4.74M | 4.41M | 4.20M | 4.18M | 4.11M |
| Average Diluted Shares Outstanding | 4.74M | 4.41M | 4.20M | 4.18M | 4.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |